Document resource
The 2024 European Society of Cardiology (ESC) Guidelines on elevated blood pressure (BP) and hypertension reflect a shift from binary thresholds towards a risk-based management approach that aims to reflect the continuous relationship between BP and cardiovascular disease (CVD).1 2 Specifically, rather than providing treatment recommendations based solely on a binary hypertension threshold of BP ≥140/90 mm Hg, the 2024 ESC Guidelines expand treatment recommendations to a broader range of adults who benefit from BP lowering. To this end, the ESC endorses the following categorisation of BP: (1) Non-elevated (office BP <120/70 mm Hg) for which drug treatment is not recommended; (2) Elevated (120–139/70–89 mm Hg) for which drug treatment is recommended based on high CVD risk and follow-up systolic BP level ≥130 mm Hg after 3 months of lifestyle intervention; and (3) Hypertension (≥140/90 mm Hg) for which prompt confirmation and drug treatment are recommended in most individuals.1